Skip to main content

Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation

Abstract

Objective

Lipoproteins modulate vascular cell function in inflammation. In this study, we analyzed whether plasma concentrations of lipoproteins and apolipoproteins in human sepsis are related to patient survival and the activation of blood monocytes and platelets.

Design

Observational study.

Setting

Medical and surgical intensive care units (ICU) of a university hospital.

Patients

151 consecutive patients after sepsis criteria had been met for the first time.

Interventions

None.

Measurements

Plasma lipoproteins, apolipoproteins, platelet CD62P-expression, monocyte HLA-DR-expression, SAPS II-scores (Simplified Acute Physiology Score) and 30-day-mortality were recorded.

Results

Total cholesterol, high-density-lipoprotein (HDL) and low-density-lipoprotein (LDL) cholesterol, apolipoprotein (apo)-AI and apo-B were all found to be significantly lower in non-survivors than in survivors. In contrast to other (apo)lipoproteins, apo-AI and HDL cholesterol further decreased in non-survivors during the ICU stay. Logistic regression analysis revealed apo-AI to be an independent predictor of 30-day-mortality. A significant inverse correlation was found for apo-AI/HDL-cholesterol and platelet activation. Later in the course of the disease, HLA-DR expression on monocytes correlated positively to apo-AI and apo-CI concentrations and inversely to the apo-E concentration.

Conclusion

Low apo-AI is independently related to 30-day mortality in human sepsis and the decrease in apo-AI/HDL cholesterol correlates to increased platelet activation. Moreover, changes in apolipoproteins supposed to modulate lipopolysaccharide effects, such as apo-CI and apo-E, correlate to monocyte activation.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. Hoesel LM, Gao H, Ward PA (2006) New insights into cellular mechanisms during sepsis. Immunol Res 34:133–141

    Article  CAS  PubMed  Google Scholar 

  2. Murch O, Collin M, Hinds CJ, Thiemermann C (2007) Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med 33:13–24

    Article  CAS  PubMed  Google Scholar 

  3. Ma J, Dempsey AA, Stamatiou D, Marshall KW, Liew CC (2007) Identifying leukocyte gene expression patterns associated with plasma lipid levels in human subjects. Atherosclerosis 191:63–72

    Article  CAS  PubMed  Google Scholar 

  4. Berbee JF, Havekes LM, Rensen PC (2005) Apolipoproteins modulate the inflammatory response to lipopolysaccharide. J Endotoxin Res 11:97–103

    CAS  PubMed  Google Scholar 

  5. Birjmohun RS, van Leuven SI, Levels JH, van ‘t Veer C, Kuivenhoven JA, Meijers JC, Levi M, Kastelein JJ, van der Poll T, Stroes ES (2007) High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. Arterioscler Thromb Vasc Biol 27:1153–1158

    Article  CAS  PubMed  Google Scholar 

  6. McDonald MC, Dhadly P, Cockerill GW, Cuzzocrea S, Mota-Filipe H, Hinds CJ, Miller NE, Thiemermann C (2003) Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock. Shock 20:551–557

    Article  CAS  PubMed  Google Scholar 

  7. Mineo C, Shaul PW (2003) HDL stimulation of endothelial nitric oxide synthase: a novel mechanism of HDL action. Trends Cardiovasc Med 13:226–231

    Article  CAS  PubMed  Google Scholar 

  8. Nofer JR, Walter M, Kehrel B, Seedorf U, Assmann G (1998) HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1, 2-diacylglycerol and inositol 1, 4, 5-tris-phosphate. Arterioscler Thromb Vasc Biol 18:861–869

    CAS  PubMed  Google Scholar 

  9. Lerch PG, Spycher MO, Doran JE (1998) Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo. Thromb Haemost 80:316–320

    CAS  PubMed  Google Scholar 

  10. Liao XL, Lou B, Ma J, Wu MP (2005) Neutrophils activation can be diminished by apolipoprotein A-I. Life Sci 77:325–335

    Article  CAS  PubMed  Google Scholar 

  11. Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, McCormick SP, Remaley AT, Sviridov D, Chin-Dusting J (2008) High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 28:2071–2077

    Article  CAS  PubMed  Google Scholar 

  12. Van Oosten M, Rensen PC, Van Amersfoort ES, Van Eck M, Van Dam AM, Breve JJ, Vogel T, Panet A, Van Berkel TJ, Kuiper J (2001) Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis. J Biol Chem 276:8820–8824

    Article  PubMed  Google Scholar 

  13. Rensen PC, Oosten M, Bilt E, Eck M, Kuiper J, Berkel TJ (1997) Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats In vivo. J Clin Invest 99:2438–2445

    Article  CAS  PubMed  Google Scholar 

  14. de Bont N, Netea MG, Demacker PN, Kullberg BJ, van der Meer JW, Stalenhoef AF (2000) Apolipoprotein E-deficient mice have an impaired immune response to Klebsiella pneumoniae. Eur J Clin Invest 30:818–822

    Article  PubMed  Google Scholar 

  15. Li Y, Dong JB, Wu MP (2008) Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice. Eur J Pharmacol 590:417–422

    Article  CAS  PubMed  Google Scholar 

  16. Berbee JF, van der Hoogt CC, Kleemann R, Schippers EF, Kitchens RL, van Dissel JT, Bakker-Woudenberg IA, Havekes LM, Rensen PC (2006) Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in gram-negative sepsis. FASEB J 20:2162–2164

    Article  CAS  PubMed  Google Scholar 

  17. Schippers EF, Berbée JF, van Disseldorp IM, Versteegh MI, Havekes LM, Rensen PC, van Dissel JT (2008) Preoperative apolipoprotein CI levels correlate positively with the proinflammatory response in patients experiencing endotoxemia following elective cardiac surgery. Intensive Care Med 34:1492–1497

    Article  PubMed  Google Scholar 

  18. Berbée JF, Mooijaart SP, de Craen AJ, Havekes LM, van Heemst D, Rensen PC, Westendorp RG (2008) Plasma apolipoprotein CI protects against mortality from infection in old age. J Gerontol A Biol Sci Med Sci 63:122–126

    PubMed  Google Scholar 

  19. Chien JY, Jerng JS, Yu CJ, Yang PC (2005) Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med 33:1688–1693

    Article  CAS  PubMed  Google Scholar 

  20. Vermont CL, den Brinker M, Kakeci N, de Kleijn ED, de Rijke YB, Joosten KF, de Groot R, Hazelzet JA (2005) Serum lipids and disease severity in children with severe meningococcal sepsis. Crit Care Med 33:1610–1615

    Article  CAS  PubMed  Google Scholar 

  21. Barlage S, Frohlich D, Bottcher A, Jauhiainen M, Müller HP, Noetzel F, Rothe G, Schütt C, Linke RP, Lackner KJ, Ehnholm C, Schmitz G (2001) ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J Lipid Res 42:281–290

    CAS  PubMed  Google Scholar 

  22. Chenaud C, Merlani PG, Bandshapp O, Ricou B (2006) Serum lipids or apolipoprotein A-I and disease severity of meningococcal sepsis. Crit Care Med 34:270–271

    Article  PubMed  Google Scholar 

  23. American College of Chest Physicians/Society of Critical Care Medicine (1992) Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874

    Article  Google Scholar 

  24. Reinhart K, Brunkhorst F, Bone H, Gerlach H, Gründling M, Kreymann G, Kujath P, Marggraf G, Mayer K, Meier-Hellmann A, Peckelsen C, Putensen C, Quintel M, Ragaller M, Rossaint R, Stüber F, Weiler N, Welte T, Werdan K, Deutsche Sepsis-Gesellschaft eV (2006) Diagnosis and therapy of sepsis: guidelines of the German Sepsis Society Inc. and the German Interdisciplinary Society for Intensive and Emergency Medicine. Anaesthesist 55(Suppl 1):43–56

    PubMed  Google Scholar 

  25. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502

    CAS  PubMed  Google Scholar 

  26. Walldius G, Jungner I (2007) Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke. Curr Opin Cardiol 22:359–367

    Article  PubMed  Google Scholar 

  27. Volk HD, Reinke P, Krausch D, Zuckermann H, Asadullah K, Müller JM, Döcke WD, Kox WJ (1996) Monocyte deactivation-rationale for a new therapeutic strategy in sepsis. Intensive Care Med 22(Suppl 4):S474–S481

    Article  PubMed  Google Scholar 

  28. Russwurm S, Vickers J, Meier-Hellmann A, Spangenberg P, Bredle D, Reinhart K, Lösche W (2002) Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. Shock 17:263–268

    Article  PubMed  Google Scholar 

  29. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP (2008) Multiple actions of high-density lipoprotein. Curr Opin Cardiol 23:370–378

    Article  PubMed  Google Scholar 

  30. Barlage S, Boettcher D, Boettcher A, Dada A, Schmitz G (2006) High density lipoprotein modulates platelet function. Cytometry A 69:196–199

    PubMed  Google Scholar 

  31. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G (2006) Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 32:75–79

    Article  PubMed  Google Scholar 

  32. Novack V, Eisinger M, Frenkel A, Terblanche M, Adhikari NK, Douvdevani A, Amichay D, Almog Y (2009) The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med 35:1255–1260

    Article  CAS  PubMed  Google Scholar 

  33. Pajkrt D, Doran JE, Koster F (1996) Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 184:1601–1608

    Article  CAS  PubMed  Google Scholar 

  34. Galbois A, Thabut D, Tazi KA, Rudler M, Mohammadi MS, Bonnefont-Rousselot D, Bennani H, Bezeaud A, Tellier Z, Guichard C, Coant N, Ogier-Denis E, Moreau R, Lebrec D (2009) Ex vivo effects of high-density lipoprotein exposure on the lipopolysaccharide-induced inflammatory response in patients with severe cirrhosis. Hepatology 49:175–184

    Article  CAS  PubMed  Google Scholar 

  35. Gupta H, Dai L, Datta G, Garber DW, Grenett H, Li Y, Mishra V, Palgunachari MN, Handattu S, Gianturco SH, Bradley WA, Anantharamaiah GM, White CR (2005) Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res 97:236–243

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gerd Schmitz.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Barlage, S., Gnewuch, C., Liebisch, G. et al. Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation. Intensive Care Med 35, 1877–1885 (2009). https://doi.org/10.1007/s00134-009-1609-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-009-1609-y

Keywords

  • Sepsis
  • HDL
  • Apolipoprotein
  • Platelet
  • Monocyte